What Is the Best Time to Take Antihypertensives?

Bedtime hypertensive therapy might reduce the risk of cardiovascular events according to this study soon to be published in Eur Heart J. However, despite showing significant risk reduction this hypothesis calls for further study before radically changing the usual upon awakening therapy. 

¿Cuál es el mejor momento del día para administrar antihipertensivos?

Taking the prescribed medication before bedtime could allow our bodies to naturally follow its circadian rhythms, boosting medication effect, improving blood pressure control and, ultimately, reducing cardiovascular events. 

This study is, without question, the largest to assess blood pressure medication time intake and the one with longest follow-up. It was carried out in several primary healthcare centers and, therefore, should reflect the daily practice. 

The Hygia Chronotherapy Trial randomized over 19000 hypertensive patients to taking medication upon awakening (angiotensin blockers, angiotensin converting enzyme inhibitors, calcium blockers, beta blockers and/or diuretics) vs. at bedtime. 


Read also: Prosthesis Mismatch in Supra and Intra Annular valves.


After a mean 6.3-year follow-up, patients taking their medication before going to bed had better systolic and diastolic blood pressure control.

In addition, a much smaller group of patients taking medication at bedtime qualified as “nondippers” (when blood pressure drops less than 10% while sleeping) vs. morning intake (37% vs 50%, p=0.001).

Finally, and most importantly, bedtime therapy reduced 45% primary end point risk, a composite of cardiovascular death, acute MI, coronary revascularization, cardiac failure and any stroke (p<0.001).

Some of the study data raises questions about the fact that bedtime therapy did not change daytime blood pressure readings vs. morning therapy.



Read also: Subintimal vs. Intraplaque Coronary Rechanneling. Do Results Vary?


For some experts, it seems hard to explain why reducing blood pressure while sleeping translates in such a significant reduction in events. One possible explanation, that requires validation, is that reducing blood pressure during sleep-time might have a pleiotropic effect that exceeds reduction readings per se. 

Original title: Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial.

Reference: Hermida RC et al. Eur Heart J. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...